Piper Sandler analyst Jason Bednar raised the firm’s price target on Envista (NVST) to $25 from $21 and keeps a Neutral rating on the shares. The firm notes Q4 was better than even the more bullish expectations, even if excluding some of the one-time/non-recurring elements that benefited. But what Piper struggles with is the juxtaposition of the 2025 experience that appears to have been consistently sandbagged against 2026 guidance that looks more realistic based on general dental market dynamics.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVST:
- Leerink upgrades Envista to Outperform on improved growth, execution
- Envista upgraded to Outperform from Market Perform at William Blair
- Envista upgraded to Outperform from Market Perform at Leerink
- Envista reports Q4 adjusted EPS 38c, consensus 32c
- Envista sees 2026 adjusted EPS $1.35-$1.45, consensus $1.28